Stay updated on Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page
- Check5 days agoChange DetectedThe page's revision metadata was updated from v3.5.3 to v3.5.4, representing a small version bump. This change does not modify visible content or behavior.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedThe page’s displayed site revision/version number was updated from v3.5.2 to v3.5.3, reflecting a minor backend or UI release rather than a change to the trial record content.SummaryDifference0.0%

- Check34 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check63 days agoChange DetectedRevision tag updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check70 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 was removed.SummaryDifference0.0%

- Check98 days agoChange DetectedAdded Revision: v3.4.2 and removed the government funding lapse notice (Revision: v3.4.1) on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page.